InDex Pharmaceuticals

Jenny Sundqvist and Johan Giléus will both remain in their positions and at the company’s disposal until their last day of employment.

"I would like to thank Jenny and Johan for their valuable contributions and for a very good collaboration. Unfortunately, our phase III study did not deliver as we had hoped for, and all current operations are being closed down. I wish both Jenny and Johan the best of luck and am certain that they will be as appreciated in their next endeavors as they have been at InDex," said Wenche Rolfsen, Chairman of the Board of InDex Pharmaceuticals.

For more information:
Wenche Rolfsen, Chairman
Phone: +46 8 122 038 50
E-mail: info@indexpharma.com

Publication
The information was submitted for publication through the agency of the contact person set out above at 16.55 CET on March 26, 2024.

This is an English translation of the Swedish press release. In case of discrepancies between the English translation and the Swedish press release, the Swedish press release shall prevail. Information in this press release is intended for investors.

InDex Pharmaceuticals in brief
InDex Pharmaceuticals has a vision to help patients with immunological diseases where there is a high unmet medical need. Cobitolimod was being evaluated in the phase III program CONCLUDE for moderate to severe left-sided ulcerative colitis – a debilitating, chronic inflammation of the large intestine.

InDex Pharmaceuticals is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm. Redeye AB is the company’s Certified Adviser. For more information, please visit www.indexpharma.com.